secwatch.observer — SEC 8-K summary
======================================

Issuer:     VOLITIONRX LTD (VNRX)
CIK:        0000093314
Form:       8-K
Filed at:   2023-12-05T23:59:59+00:00
Accession:  0001477932-23-008963
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VolitionRx secures ~$5.5M financing from Belgian regional government WE
-----------------------------------------------------------------------

- Total financing €5.0M (~$5.5M) from Wallonie Entreprendre; €2.5M unsecured loan at 8% interest, maturity Dec 2028.
- €2.5M equity component: WE purchases 3,205,431 restricted shares at $0.8337 per share.
- Proceeds for Nu.Q product development, including Nu.Q NETs sepsis diagnostic clinical program.
- Loan drawable in three tranches: €1.5M immediate, €0.5M from June 2024, €0.5M from March 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/93314/000147793223008963/0001477932-23-008963-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/93314/000147793223008963/vnrx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-23-008963

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer